Advances in clinical trial design for development of new TB treatments—Translating international tuberculosis treatment guidelines into national strategic plans: Experiences from Belarus, South Africa, and Vietnam

About the Authors: Grania Brigden * E-mail: grania.brigden@theunion.org Affiliation: Department of Tuberculosis, The International Union Against TB and Lung Disease, Geneva, Switzerland ORCID logo http://orcid.org/0000-0001-5184-4121 Nguyen Viet Nhung Affiliation: National Lung Hospital, Vietnam NTP...

Full description

Saved in:
Bibliographic Details
Published in:PLoS medicine Vol. 16; no. 10; p. e1002896
Main Authors: Brigden, Grania, Nhung, Nguyen Viet, Skrahina, Alena, Ndjeka, Norbert, Falzon, Dennis, Zignol, Matteo
Format: Journal Article
Language:English
Published: United States Public Library of Science 18.10.2019
Public Library of Science (PLoS)
Subjects:
ISSN:1549-1676, 1549-1277, 1549-1676
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:About the Authors: Grania Brigden * E-mail: grania.brigden@theunion.org Affiliation: Department of Tuberculosis, The International Union Against TB and Lung Disease, Geneva, Switzerland ORCID logo http://orcid.org/0000-0001-5184-4121 Nguyen Viet Nhung Affiliation: National Lung Hospital, Vietnam NTP, Vietnam Alena Skrahina Affiliation: Republican Scientific and Practical Centre for Pulmonology and TB, Minsk, Belarus Norbert Ndjeka Affiliation: Drug-Resistant TB, TB and HIV directorate, National Department of Health, Pretoria, South Africa Dennis Falzon Affiliation: Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland ORCID logo http://orcid.org/0000-0001-8798-7909 Matteo Zignol Affiliation: Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland Introduction One of the key missions of national tuberculosis (TB) programmes (NTPs) is to issue policy and technical guidance for clinicians and healthcare workers involved in TB care at the country level. Translating research findings into policies may be a challenging task, given that the design of clinical studies may not always address the main public health priority directly, and recommended interventions require substantial adaptation to the particular programme conditions and settings [4]. A recent review [17] of national policies in 29 countries highlighted national policy gaps when compared to WHO policies. [...]in the case of WHO’s recommended 9–12-month-shorter MDR-TB regimen, 45% of the countries had developed policies, but only 69% of those countries had implemented them. Since late 2018, the NTP introduced under operational research conditions a shorter regimen of 9 months consisting of all group A and B medicines recommended in MDR-TB regimens.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
The authors have declared that no competing interests exist.
ISSN:1549-1676
1549-1277
1549-1676
DOI:10.1371/journal.pmed.1002896